Alembic Pharmaceuticals' Consolidated Profit Declines in Fiscal Q3

MT Newswires Live

Feb 05

Alembic Pharmaceuticals' (NSE:APLLTD, BOM:533573) consolidated profit rose to 1.33 billion Indian rupees in the fiscal third quarter ended Dec. 31, 2025, from 1.38 billion rupees a year ago.

Earnings per share contracted to 6.76 rupees from 7.01 rupees a year earlier, the pharmaceutical company said in a filing to the Indian stock exchanges on Thursday.

Revenue from operations in fiscal Q3, however, increased to 18.8 billion rupees from 16.9 billion rupees a year ago.

The company's shares were up nearly 2% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2609037566"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609037566\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609037566?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 18:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609037566","market":"sh","top_or_hot":-1,"title":"Alembic Pharmaceuticals' Consolidated Profit Declines in Fiscal Q3","media":"MT Newswires Live","content":"<html><body><p> Alembic Pharmaceuticals' (NSE:APLLTD, BOM:533573) consolidated profit rose to 1.33 billion Indian rupees in the fiscal third quarter ended Dec. 31, 2025, from 1.38 billion rupees a year ago.</p><p>Earnings per share contracted to 6.76 rupees from 7.01 rupees a year earlier, the pharmaceutical company said in a filing to the Indian stock exchanges on Thursday.</p><p>Revenue from operations in fiscal Q3, however, increased to 18.8 billion rupees from 16.9 billion rupees a year ago.</p><p>The company's shares were up nearly 2% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alembic Pharmaceuticals' Consolidated Profit Declines in Fiscal Q3</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlembic Pharmaceuticals' Consolidated Profit Declines in Fiscal Q3\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-05 18:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Alembic Pharmaceuticals' (NSE:APLLTD, BOM:533573) consolidated profit rose to 1.33 billion Indian rupees in the fiscal third quarter ended Dec. 31, 2025, from 1.38 billion rupees a year ago.</p><p>Earnings per share contracted to 6.76 rupees from 7.01 rupees a year earlier, the pharmaceutical company said in a filing to the Indian stock exchanges on Thursday.</p><p>Revenue from operations in fiscal Q3, however, increased to 18.8 billion rupees from 16.9 billion rupees a year ago.</p><p>The company's shares were up nearly 2% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CNSL","symbol_name":"联合通讯","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2609037566","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609037566","pubTimestamp":1770287740,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Alembic Pharmaceuticals'  consolidated profit rose to 1.33 billion Indian rupees in the fiscal third quarter ended Dec. 31, 2025, from 1.38 billion rupees a year ago.Earnings per share contracted to 6.76 rupees from 7.01 rupees a year earlier, the pharmaceutical company said in a filing to the Indian stock exchanges on Thursday.Revenue from operations in fiscal Q3, however, increased to 18.8 billion rupees from 16.9 billion rupees a year ago.The company's shares were up nearly 2% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CNSL":"联合通讯","BK4115":"综合电信业务"},"translate_title":"Alembic Pharmaceuticals第三财季综合利润下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNSL":1.5},"content_text":"Alembic Pharmaceuticals' (NSE:APLLTD, BOM:533573) consolidated profit rose to 1.33 billion Indian rupees in the fiscal third quarter ended Dec. 31, 2025, from 1.38 billion rupees a year ago.Earnings per share contracted to 6.76 rupees from 7.01 rupees a year earlier, the pharmaceutical company said in a filing to the Indian stock exchanges on Thursday.Revenue from operations in fiscal Q3, however, increased to 18.8 billion rupees from 16.9 billion rupees a year ago.The company's shares were up nearly 2% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}